

Anant Ramaswamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6304869/publications.pdf>

Version: 2024-02-01

94
papers

658
citations

759233

12
h-index

794594

19
g-index

95
all docs

95
docs citations

95
times ranked

862
citing authors

#	ARTICLE	IF	CITATIONS
1	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. <i>American Journal of Surgery</i> , 2022, 223, 1055-1062.	1.8	5
2	Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 995-1005.	1.3	1
3	Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). <i>Oncologist</i> , 2022, 27, 165-e222.	3.7	12
4	G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer. <i>Journal of Geriatric Oncology</i> , 2022, 13, 720-730.	1.0	7
5	Addressing the Needs of Older Adults With Cancer in Low- and Middle-Income Settings. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 384-393.	3.8	1
6	Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 147-151.	0.9	2
7	Development of a New Tool to Assess the Quality of Life of Patients with Handâ€œFoot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study. <i>South Asian Journal of Cancer</i> , 2022, 11, 019-023.	0.6	1
8	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant <sup>18</sup><sup>F</sup>FDG Uptake. <i>Neuroendocrinology</i> , 2021, 111, 998-1004.	2.5	19
9	Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e70-e76.	1.1	4
10	Revision Surgery for Incidental Gallbladder Cancerâ€œChallenging the Dogma: Ideal Timing and Real-World Applicability. <i>Annals of Surgical Oncology</i> , 2021, 28, 6758-6766.	1.5	14
11	Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 821-831.	1.9	4
12	Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer. <i>JAMA Oncology</i> , 2021, 7, 436.	7.1	16
13	Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e047376.	1.9	21
14	Towards standardization of management of gallbladder carcinoma with obstructive jaundice: Analysis of 113 cases over 10 years at a single institution. <i>Journal of Surgical Oncology</i> , 2021, 124, 572-580.	1.7	7
15	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	6
16	ASO Visual Abstract: Pathologic N3 Stage (pN3/ypN3) Gastric Cancerâ€œOutcomes, Prognostic Factors, and Pattern of Recurrences after Curative Treatment. <i>Annals of Surgical Oncology</i> , 2021, 28, 587.	1.5	0
17	Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 664-670.	0.7	5
18	Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India. <i>Frontiers in Oncology</i> , 2021, 11, 710585.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 24-31.	1.1	1
20	Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nuclear Medicine Communications, 2021, 42, 337-344.	1.1	3
21	Older patients with cancer require and deserve more!. Indian Journal of Cancer, 2021, 58, 479.	0.2	0
22	Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas – are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?. Hpb, 2020, 22, 376-382.	0.3	9
23	COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Medicine, 2020, 9, 8747-8753.	2.8	29
24	Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4. Journal of Gastrointestinal Cancer, 2020, 51, 703-708.	1.3	2
25	Comparison of treatment plans feasible through AI enabled multidisciplinary online tumor board solution versus NCCN-based clinical decision support system (CDSS).. Journal of Clinical Oncology, 2020, 38, 816-816.	1.6	0
26	A prospective analysis of chemotherapy-induced nausea and vomiting in gastrointestinal cancers: Results from a tertiary cancer center.. Journal of Clinical Oncology, 2020, 38, 12111-12111.	1.6	1
27	Gastrointestinal Stromal Tumor – An Overview. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 809-818.	0.2	1
28	Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas – A Relatively Rare Component of Biliary Tract Cancers in India. South Asian Journal of Cancer, 2020, 09, 209-212.	0.6	2
29	Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?. South Asian Journal of Cancer, 2020, 09, 245-249.	0.6	1
30	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 2019, 9, e028147.	1.9	14
31	Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 2232-2238.	1.7	6
32	Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. Journal of Gastrointestinal Cancer, 2019, 50, 298-303.	1.3	18
33	Management of colon cancer at a tertiary referral center in India - Patterns of presentation, treatment, and survival outcomes. Indian Journal of Cancer, 2019, 56, 297.	0.2	6
34	Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 165-171.	0.2	5
35	Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report. South Asian Journal of Cancer, 2019, 08, 225-240.	0.6	2
36	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian Journal of Cancer, 2019, 08, 092-097.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer, 2019, 08, 22-26.	0.6	2
38	Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers. South Asian Journal of Cancer, 2019, 08, 166-167.	0.6	3
39	Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian Journal of Cancer, 2019, 08, 160-165.	0.6	0
40	Outcome of neoadjuvant chemotherapy in locally advanced/borderline resectable gallbladder cancer: the need to define indications. Hpb, 2018, 20, 841-847.	0.3	50
41	Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Medical Oncology, 2018, 35, 57.	2.5	7
42	Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. Journal of Surgical Oncology, 2018, 117, 372-379.	1.7	29
43	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. Journal of Gastrointestinal Oncology, 2018, 10, 19-29.	1.4	12
44	Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors. Nuclear Medicine Communications, 2018, 39, 1143-1149.	1.1	14
45	Resection of Isolated Port Site Metastasis in Gall Bladder Cancers-Careful Selection and Perioperative Systemic Therapy May Improve Outcomes. Indian Journal of Surgical Oncology, 2018, 9, 427-431.	0.7	4
46	Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. Indian Journal of Cancer, 2018, 55, 88.	0.2	3
47	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. Indian Journal of Cancer, 2018, 55, 138.	0.2	5
48	An evaluation of early-onset fatigue and the related coping strategies in patients with gastrointestinal cancer: A prospective pilot study. Indian Journal of Cancer, 2018, 55, 162.	0.2	3
49	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian Journal of Medical Research, 2018, 148, 284.	1.0	5
50	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.7	3
51	Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. South Asian Journal of Cancer, 2018, 07, 226-230.	0.6	5
52	Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. South Asian Journal of Cancer, 2018, 07, 219-222.	0.6	2
53	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.6	8
54	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. <i>Indian Journal of Cancer</i> , 2018, 55, 144.	0.2	2
56	Up-front short-course radiotherapy and systemic chemotherapy for locally advanced rectal cancers with distant metastasis: Does it provide meaningful benefit?. <i>Journal of Clinical Oncology</i> , 2018, 36, 778-778.	1.6	0
57	Early survival outcomes in stage I-III operated colon cancer patients from a low prevalence, lower-middle income country: The Indian experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 857-857.	1.6	0
58	Prevalence of MSI status in locally advanced rectal cancer and its correlation with response to neoadjuvant therapy and survival.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15668-e15668.	1.6	0
59	Influence of hypothyroidism post chemo radiation on outcomes in head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18066-e18066.	1.6	0
60	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e345-e355.	1.9	6
61	Neoadjuvant chemotherapy in geriatric head and neck cancers. <i>Head and Neck</i> , 2017, 39, 886-892.	2.0	5
62	Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 262-267.	2.6	14
63	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168.	4.5	48
64	A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 100-102.	1.3	4
65	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. <i>Journal of Gastric Cancer</i> , 2017, 17, 21.	2.5	10
66	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. <i>Chemotherapy Research and Practice</i> , 2017, 2017, 1-4.	1.6	1
67	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed+carboplatin chemotherapy. <i>Ecancermedicalscience</i> , 2017, 11, 776.	1.1	2
68	Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. <i>Journal of Oncology Practice</i> , 2017, 13, e574-e581.	2.5	10
69	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 346-359.	0.5	3
70	Treatment of advanced Gall bladder cancer in the real world—can continuation chemotherapy improve outcomes?. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 368-376.	1.4	9
71	What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 94-94.	3.0	1
72	Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. <i>Annals of Translational Medicine</i> , 2017, 5, 134-134.	1.7	11

#	ARTICLE	IF	CITATIONS
73	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. South Asian Journal of Cancer, 2017, 06, 186-189.	0.6	4
74	Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience. South Asian Journal of Cancer, 2017, 06, 113-117.	0.6	9
75	Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian Journal of Cancer, 2017, 06, 110-112.	0.6	5
76	Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian Journal of Cancer, 2017, 06, 144-146.	0.6	7
77	Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Indian Journal of Cancer, 2017, 54, 530.	0.2	3
78	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.2	0
79	Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India. Indian Journal of Radiology and Imaging, 2017, 27, 200-206.	0.8	3
80	Upfront short course radiotherapy (SCRT) in metastatic rectal cancer (mRC): A way forward.. Journal of Clinical Oncology, 2017, 35, 3570-3570.	1.6	0
81	Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor- positive metastatic breast cancer – A retrospective pilot analysis and viewpoint. South Asian Journal of Cancer, 2017, 06, 102-105.	0.6	1
82	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. Journal of Gastrointestinal Oncology, 2016, 7, 380-386.	1.4	13
83	Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. Journal of Gastrointestinal Oncology, 2016, 7, 624-631.	1.4	12
84	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLoS ONE, 2016, 11, e0160752.	2.5	28
85	Technically unresectable recurrent oral cancers: Is NACT the answer?. Oral Oncology, 2016, 56, e12-e14.	1.5	1
86	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	1.5	16
87	Rectal GIST – Outcomes and viewpoint from a tertiary cancer center. Indian Journal of Gastroenterology, 2016, 35, 445-449.	1.4	7
88	Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian Journal of Cancer, 2016, 05, 067-069.	0.6	7
89	Indian data on bone and soft tissue sarcomas: A summary of published study results. South Asian Journal of Cancer, 2016, 05, 138-145.	0.6	14
90	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian Journal of Cancer, 2016, 05, 182-185.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine-based regimens: A retrospective tertiary care centre experience.. Journal of Clinical Oncology, 2016, 34, 712-712.	1.6	0
92	Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO's antiemetic clinical guideline.. Journal of Clinical Oncology, 2016, 34, e18230-e18230.	1.6	0
93	An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian Journal of Cancer, 0, , .	0.6	1
94	The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer. South Asian Journal of Cancer, 0, , .	0.6	0